Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced that Fermion’s FZ008-145 has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for pain treatment in China.
Fermion, which previously granted Joincare exclusive rights to the drug in Greater China while retaining rights outside the region, will see Joincare take the lead on the ensuing clinical study, regulatory filings, and other related responsibilities, including acting as the Marketing Authorization Holder (MAH) for FZ008-145.
FZ008-145 is noted as the world’s second and first highly selective second-generation Nav1.8 inhibitor. The drug works by blocking the Nav1.8 channel, which inhibits the transmission of pain signals from the peripheral nervous system to the central nervous system, resulting in analgesic effects.- Flcube.com
